drugset
drugset / Trial / NCT04293809

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation

NCT04293809 ↗

Phase 1 Completed 30 enrolled Pacira Pharmaceuticals, Inc
RandomizedSequentialOpen-labelTreatment

Summary

This is a pilot, open label, single center study in 30 women undergoing breast augmentation. The study will assess and collect information on pharmacokinetics and safety of EXPAREL administered as a pectoral plane block. A total of 15 subjects will be enrolled in each of the 2 cohorts.

Timeline

Start
2019-12-19
Primary completion
2020-01-15
Completion
2020-01-29

Drugs

EvaluationDrugModalityDoseRoute
Background Bupivacaine Other / unclassified 266 mg Other
Background Bupivacaine Other / unclassified 150 mg —

Indications

No indication recorded.